These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
||||||||||
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
||||||||||
|
|
|
|||||||
|
(State or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification No.) |
|||||||
|
|
|
||||||||||
|
|
|
(Zip Code) | |||||||||
| (Address of principal executive offices) | |||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
|
|
|
|
||||||||||||
|
|
||||||||||||||
|
|
☒
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
|
Emerging growth company
|
|
||||||||||||||||||||
| Item Number |
Page
Number |
|||||||
| 1. | ||||||||
| 2. | ||||||||
| 3. | ||||||||
| 4. | ||||||||
| PART II | ||||||||
| 1 | ||||||||
| 6 | ||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions, except per share data) | 2023 |
2022
(1)
|
2023 |
2022
(1)
|
|||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Net earned premiums | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Net investment income |
|
|
|
|
|||||||||||||||||||
| Net investment losses |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Non-insurance warranty revenue |
|
|
|
|
|||||||||||||||||||
| Other revenues |
|
|
|
|
|||||||||||||||||||
| Total revenues |
|
|
|
|
|||||||||||||||||||
| Claims, Benefits and Expenses | |||||||||||||||||||||||
|
Insurance claims and policyholders’ benefits (re-measurement gain (loss) of $(
|
|
|
|
|
|||||||||||||||||||
| Amortization of deferred acquisition costs |
|
|
|
|
|||||||||||||||||||
| Non-insurance warranty expense |
|
|
|
|
|||||||||||||||||||
| Other operating expenses |
|
|
|
|
|||||||||||||||||||
| Interest |
|
|
|
|
|||||||||||||||||||
| Total claims, benefits and expenses |
|
|
|
|
|||||||||||||||||||
| Income (loss) before income tax |
|
(
|
|
|
|||||||||||||||||||
| Income tax (expense) benefit |
(
|
|
(
|
(
|
|||||||||||||||||||
| Net income (loss) | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Basic earnings (loss) per share | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Diluted earnings (loss) per share | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Weighted Average Outstanding Common Stock and Common Stock Equivalents | |||||||||||||||||||||||
| Basic |
|
|
|
|
|||||||||||||||||||
| Diluted |
|
|
|
|
|||||||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 |
2022
(1)
|
2023 |
2022
(1)
|
|||||||||||||||||||
| Comprehensive (Loss) Income | |||||||||||||||||||||||
| Net income (loss) | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Other Comprehensive Loss, net of tax | |||||||||||||||||||||||
| Changes in: | |||||||||||||||||||||||
| Net unrealized gains and losses on investments with an allowance for credit losses |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Net unrealized gains and losses on other investments |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Net unrealized gains and losses on investments |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Impact of changes in discount rates used to measure long-duration contract liabilities |
|
|
|
|
|||||||||||||||||||
| Foreign currency translation adjustment |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Pension and postretirement benefits |
|
|
|
|
|||||||||||||||||||
| Other comprehensive loss, net of tax |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Total comprehensive (loss) income | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| (In millions, except share data) | September 30, 2023 |
December 31, 2022
(1)
|
|||||||||
| Assets | |||||||||||
| Investments: | |||||||||||
|
Fixed maturity securities at fair value (amortized cost of $
|
$ |
|
$ |
|
|||||||
|
Equity securities at fair value (cost of $
|
|
|
|||||||||
| Limited partnership investments |
|
|
|||||||||
| Other invested assets |
|
|
|||||||||
|
Mortgage loans (less allowance for uncollectible receivables of $
|
|
|
|||||||||
| Short term investments |
|
|
|||||||||
| Total investments |
|
|
|||||||||
| Cash |
|
|
|||||||||
|
Reinsurance receivables (less allowance for uncollectible receivables of $
|
|
|
|||||||||
|
Insurance receivables (less allowance for uncollectible receivables of $
|
|
|
|||||||||
| Accrued investment income |
|
|
|||||||||
| Deferred acquisition costs |
|
|
|||||||||
| Deferred income taxes |
|
|
|||||||||
|
Property and equipment at cost (less accumulated depreciation of $
|
|
|
|||||||||
| Goodwill |
|
|
|||||||||
| Deferred non-insurance warranty acquisition expense |
|
|
|||||||||
|
Other assets (includes $
|
|
|
|||||||||
| Total assets | $ |
|
$ |
|
|||||||
| Liabilities | |||||||||||
| Insurance reserves: | |||||||||||
| Claim and claim adjustment expenses | $ |
|
$ |
|
|||||||
| Unearned premiums |
|
|
|||||||||
| Future policy benefits |
|
|
|||||||||
| Short term debt |
|
|
|||||||||
| Long term debt |
|
|
|||||||||
| Deferred non-insurance warranty revenue |
|
|
|||||||||
|
Other liabilities (includes $
|
|
|
|||||||||
| Total liabilities |
|
|
|||||||||
| Commitments and contingencies (Notes C and G) |
|
||||||||||
| Stockholders' Equity | |||||||||||
|
Common stock ($
|
|
|
|||||||||
| Additional paid-in capital |
|
|
|||||||||
| Retained earnings |
|
|
|||||||||
| Accumulated other comprehensive loss |
(
|
(
|
|||||||||
|
Treasury stock (
|
(
|
(
|
|||||||||
| Total stockholders’ equity |
|
|
|||||||||
| Total liabilities and stockholders' equity | $ |
|
$ |
|
|||||||
| Nine months ended September 30 | |||||||||||
| (In millions) | 2023 |
2022
(1)
|
|||||||||
| Cash Flows from Operating Activities | |||||||||||
| Net income | $ |
|
$ |
|
|||||||
| Adjustments to reconcile net income to net cash flows provided by operating activities: | |||||||||||
| Deferred income tax expense (benefit) |
|
(
|
|||||||||
| Trading portfolio activity |
(
|
(
|
|||||||||
| Net investment losses |
|
|
|||||||||
| Equity method investees |
|
|
|||||||||
| Net amortization of investments |
(
|
(
|
|||||||||
| Depreciation and amortization |
|
|
|||||||||
| Changes in: | |||||||||||
| Receivables, net |
(
|
(
|
|||||||||
| Accrued investment income |
(
|
(
|
|||||||||
| Deferred acquisition costs |
(
|
(
|
|||||||||
| Insurance reserves |
|
|
|||||||||
| Other, net |
(
|
(
|
|||||||||
| Net cash flows provided by operating activities |
|
|
|||||||||
| Cash Flows from Investing Activities | |||||||||||
| Dispositions: | |||||||||||
| Fixed maturity securities - sales |
|
|
|||||||||
| Fixed maturity securities - maturities, calls and redemptions |
|
|
|||||||||
| Equity securities |
|
|
|||||||||
| Limited partnerships |
|
|
|||||||||
| Mortgage loans |
|
|
|||||||||
| Purchases: | |||||||||||
| Fixed maturity securities |
(
|
(
|
|||||||||
| Equity securities |
(
|
(
|
|||||||||
| Limited partnerships |
(
|
(
|
|||||||||
| Mortgage loans |
(
|
(
|
|||||||||
| Change in other investments |
|
|
|||||||||
| Change in short term investments |
(
|
|
|||||||||
| Purchases of property and equipment |
(
|
(
|
|||||||||
| Other, net |
(
|
(
|
|||||||||
| Net cash flows used by investing activities |
(
|
(
|
|||||||||
| Cash Flows from Financing Activities | |||||||||||
| Dividends paid to common stockholders |
(
|
(
|
|||||||||
| Proceeds from the issuance of debt |
|
|
|||||||||
| Purchase of treasury stock |
(
|
(
|
|||||||||
| Other, net |
(
|
(
|
|||||||||
| Net cash flows used by financing activities |
(
|
(
|
|||||||||
| Effect of foreign exchange rate changes on cash |
|
(
|
|||||||||
| Net change in cash |
|
(
|
|||||||||
| Cash, beginning of year |
|
|
|||||||||
| Cash, end of period | $ |
|
$ |
|
|||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 |
2022
(1)
|
2023 |
2022
(1)
|
|||||||||||||||||||
| Common Stock | |||||||||||||||||||||||
| Balance, beginning of period | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Balance, end of period |
|
|
|
|
|||||||||||||||||||
| Additional Paid-in Capital | |||||||||||||||||||||||
| Balance, beginning of period |
|
|
|
|
|||||||||||||||||||
| Stock-based compensation |
|
|
(
|
(
|
|||||||||||||||||||
| Balance, end of period |
|
|
|
|
|||||||||||||||||||
| Retained Earnings | |||||||||||||||||||||||
| Balance, beginning of period, as previously reported |
|
|
|
|
|||||||||||||||||||
| Cumulative effect adjustments from changes in accounting guidance, net of tax |
|
(
|
(
|
(
|
|||||||||||||||||||
| Balance, beginning of period, as adjusted |
|
|
|
|
|||||||||||||||||||
|
Dividends to common stockholders ($
|
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Net income (loss) |
|
(
|
|
|
|||||||||||||||||||
| Balance, end of period |
|
|
|
|
|||||||||||||||||||
| Accumulated Other Comprehensive Loss | |||||||||||||||||||||||
| Balance, beginning of period, as previously reported |
(
|
(
|
(
|
|
|||||||||||||||||||
| Cumulative effect adjustments from changes in accounting guidance, net of tax |
|
(
|
(
|
(
|
|||||||||||||||||||
| Balance, beginning of period, as adjusted |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Other comprehensive loss |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Balance, end of period |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Treasury Stock | |||||||||||||||||||||||
| Balance, beginning of period |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Stock-based compensation |
|
|
|
|
|||||||||||||||||||
| Purchase of treasury stock |
|
(
|
(
|
(
|
|||||||||||||||||||
| Balance, end of period |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Total stockholders' equity | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
|
(In millions)
|
|||||
| Balance as of December 31, 2020, as previously reported | $ |
|
|||
|
Reclassification of reserves for policyholders currently receiving benefits to Future policy benefits
(1)
|
|
||||
| De-recognition of shadow reserves |
(
|
||||
| Re-measurement using an upper-medium grade fixed income instrument yield discount rate |
|
||||
| Other adjustments |
|
||||
| Balance as of January 1, 2021, as adjusted | $ |
|
|||
|
(In millions)
|
Accumulated other comprehensive income (loss) | Retained earnings | |||||||||
| Balance as of December 31, 2020, as previously reported | $ |
|
$ |
|
|||||||
| De-recognition of shadow reserves |
|
|
|||||||||
| Re-measurement of LFPB using an upper-medium grade fixed income instrument yield discount rate |
(
|
|
|||||||||
| Other adjustments |
|
(
|
|||||||||
| Balance as of January 1, 2021, as adjusted | $ |
(
|
$ |
|
|||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
|
Insurance claims and policyholders’ benefits
(1)
|
$ |
|
$ |
|
$ |
|
|||||||||||
| Income (loss) before income tax |
|
(
|
(
|
||||||||||||||
| Income tax (expense) benefit |
(
|
|
|
||||||||||||||
| Net income |
|
(
|
(
|
||||||||||||||
| Basic earnings (loss) per share |
|
(
|
(
|
||||||||||||||
| Diluted earnings (loss) per share |
|
(
|
(
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
|
Insurance claims and policyholders’ benefits
(1)
|
$ |
|
$ |
|
$ |
|
|||||||||||
| Income (loss) before income tax |
|
(
|
|
||||||||||||||
| Income tax (expense) benefit |
(
|
|
(
|
||||||||||||||
| Net income |
|
(
|
|
||||||||||||||
| Basic earnings (loss) per share |
|
(
|
|
||||||||||||||
| Diluted earnings (loss) per share |
|
(
|
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
| Deferred income taxes | $ |
|
$ |
|
$ |
|
|||||||||||
| Total assets |
|
|
|
||||||||||||||
|
Claim and claim adjustment expenses
(1)
|
|
(
|
|
||||||||||||||
|
Future policy benefits
(1)
|
|
|
|
||||||||||||||
| Total liabilities |
|
|
|
||||||||||||||
| Retained earnings |
|
(
|
|
||||||||||||||
| Accumulated other comprehensive income (loss) |
(
|
(
|
(
|
||||||||||||||
| Total stockholders' equity |
|
(
|
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
| Changes in: Net unrealized gains and losses on other investments | $ |
(
|
$ |
(
|
$ |
(
|
|||||||||||
| Net unrealized gains and losses on investments |
(
|
(
|
(
|
||||||||||||||
| Impact of changes in discount rates used to measure long-duration contract liabilities |
|
|
|
||||||||||||||
| Other comprehensive income (loss), net of tax |
(
|
|
(
|
||||||||||||||
| Total comprehensive income (loss) |
(
|
|
(
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
| Changes in: Net unrealized gains and losses on other investments | $ |
(
|
$ |
(
|
$ |
(
|
|||||||||||
| Net unrealized gains and losses on investments |
(
|
(
|
(
|
||||||||||||||
| Impact of changes in discount rates used to measure long-duration contract liabilities |
|
|
|
||||||||||||||
| Other comprehensive income (loss), net of tax |
(
|
|
(
|
||||||||||||||
| Total comprehensive income (loss) |
(
|
|
(
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
| Net income | $ |
|
$ |
(
|
$ |
|
|||||||||||
| Deferred income tax expense (benefit) |
(
|
(
|
(
|
||||||||||||||
| Changes in: Insurance reserves |
|
|
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
|
Net incurred claims and benefits
(1)
|
$ |
|
$ |
|
$ |
|
|||||||||||
| Core income (loss) before income tax |
(
|
(
|
(
|
||||||||||||||
| Income tax (expense) benefit on core income (loss) |
|
|
|
||||||||||||||
| Core income (loss) |
(
|
(
|
(
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
|
Net incurred claims and benefits
(1)
|
$ |
|
$ |
|
$ |
|
|||||||||||
| Core income (loss) before income tax |
(
|
(
|
(
|
||||||||||||||
| Income tax (expense) benefit on core income (loss) |
|
|
|
||||||||||||||
| Core income (loss) |
|
(
|
(
|
||||||||||||||
|
(In millions)
|
Prior to Adoption | Effect of Adoption | As reported | ||||||||||||||
|
Claim and claim adjustment expenses
(1)
|
$ |
|
$ |
(
|
$ |
|
|||||||||||
|
Future policy benefits
(1)
|
|
|
|
||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions, except per share data) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
|
Net income (loss)
(1)
|
$ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Common Stock and Common Stock Equivalents | |||||||||||||||||||||||
| Basic | |||||||||||||||||||||||
| Weighted average shares outstanding |
|
|
|
|
|||||||||||||||||||
| Diluted | |||||||||||||||||||||||
| Weighted average shares outstanding |
|
|
|
|
|||||||||||||||||||
| Dilutive effect of stock-based awards under compensation plans |
|
|
|
|
|||||||||||||||||||
| Total |
|
|
|
|
|||||||||||||||||||
|
Earnings (loss) per share
(1)
|
|||||||||||||||||||||||
| Basic | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Diluted | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Equity securities |
|
|
|
(
|
|||||||||||||||||||
| Limited partnership investments |
|
(
|
|
(
|
|||||||||||||||||||
| Mortgage loans |
|
|
|
|
|||||||||||||||||||
| Short term investments |
|
|
|
|
|||||||||||||||||||
| Trading portfolio |
|
|
|
|
|||||||||||||||||||
| Other |
|
|
|
|
|||||||||||||||||||
| Gross investment income |
|
|
|
|
|||||||||||||||||||
| Investment expense |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Net investment income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
|
Net investment income (loss) recognized due to the change in fair value of common stock held as of September 30, 2023 and 2022
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Net investment gains (losses): | |||||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||||
| Gross gains | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Gross losses |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Net investment gains (losses) on fixed maturity securities |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Equity securities |
|
(
|
(
|
(
|
|||||||||||||||||||
| Derivatives |
|
|
|
|
|||||||||||||||||||
| Mortgage loans |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Short term investments and other |
|
|
|
|
|||||||||||||||||||
| Net investment gains (losses) | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
|
Net investment gains (losses) recognized due to the change in fair value of non-redeemable preferred stock held as of September 30, 2023 and 2022
|
$ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Fixed maturity securities available-for-sale: | |||||||||||||||||||||||
| Corporate and other bonds | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Asset-backed |
|
|
|
|
|||||||||||||||||||
| Impairment losses (gains) recognized in earnings | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| September 30, 2023 |
Cost or
Amortized Cost |
Gross
Unrealized Gains |
Gross
Unrealized Losses |
Allowance for Credit Losses |
Estimated
Fair Value |
||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | |||||||||||||||||||||||||||||
| Corporate and other bonds | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| States, municipalities and political subdivisions |
|
|
|
|
|
||||||||||||||||||||||||
| Asset-backed: | |||||||||||||||||||||||||||||
| Residential mortgage-backed |
|
|
|
|
|
||||||||||||||||||||||||
| Commercial mortgage-backed |
|
|
|
|
|
||||||||||||||||||||||||
| Other asset-backed |
|
|
|
|
|
||||||||||||||||||||||||
| Total asset-backed |
|
|
|
|
|
||||||||||||||||||||||||
| U.S. Treasury and obligations of government-sponsored enterprises |
|
|
|
|
|
||||||||||||||||||||||||
| Foreign government |
|
|
|
|
|
||||||||||||||||||||||||
| Redeemable preferred stock |
|
|
|
|
|
||||||||||||||||||||||||
| Total fixed maturity securities available-for-sale |
|
|
|
|
|
||||||||||||||||||||||||
| Total fixed maturity securities trading |
|
— | — | — |
|
||||||||||||||||||||||||
| Total fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| December 31, 2022 |
Cost or
Amortized Cost |
Gross
Unrealized Gains |
Gross
Unrealized Losses |
Allowance for Credit Losses |
Estimated
Fair Value |
||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | |||||||||||||||||||||||||||||
| Corporate and other bonds | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| States, municipalities and political subdivisions |
|
|
|
|
|
||||||||||||||||||||||||
| Asset-backed: | |||||||||||||||||||||||||||||
| Residential mortgage-backed |
|
|
|
|
|
||||||||||||||||||||||||
| Commercial mortgage-backed |
|
|
|
|
|
||||||||||||||||||||||||
| Other asset-backed |
|
|
|
|
|
||||||||||||||||||||||||
| Total asset-backed |
|
|
|
|
|
||||||||||||||||||||||||
| U.S. Treasury and obligations of government-sponsored enterprises |
|
|
|
|
|
||||||||||||||||||||||||
| Foreign government |
|
|
|
|
|
||||||||||||||||||||||||
| Redeemable preferred stock |
|
|
|
|
|
||||||||||||||||||||||||
| Total fixed maturity securities available-for-sale |
|
|
|
|
|
||||||||||||||||||||||||
| Total fixed maturity securities trading |
|
— | — | — |
|
||||||||||||||||||||||||
| Total fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Less than 12 Months | 12 Months or Longer | Total | |||||||||||||||||||||||||||||||||
| September 30, 2023 |
Estimated
Fair Value |
Gross
Unrealized Losses |
Estimated
Fair Value |
Gross
Unrealized Losses |
Estimated
Fair Value |
Gross
Unrealized Losses |
|||||||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | |||||||||||||||||||||||||||||||||||
| Corporate and other bonds | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| States, municipalities and political subdivisions |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Asset-backed: | |||||||||||||||||||||||||||||||||||
| Residential mortgage-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Commercial mortgage-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Other asset-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total asset-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| U.S. Treasury and obligations of government-sponsored enterprises |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Foreign government |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Less than 12 Months | 12 Months or Longer | Total | |||||||||||||||||||||||||||||||||
| December 31, 2022 |
Estimated
Fair Value |
Gross
Unrealized Losses |
Estimated
Fair Value |
Gross
Unrealized Losses |
Estimated
Fair Value |
Gross
Unrealized Losses |
|||||||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | |||||||||||||||||||||||||||||||||||
| Corporate and other bonds | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| States, municipalities and political subdivisions |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Asset-backed: | |||||||||||||||||||||||||||||||||||
| Residential mortgage-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Commercial mortgage-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Other asset-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total asset-backed |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| U.S. Treasury and obligations of government-sponsored enterprises |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Foreign government |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| September 30, 2023 | December 31, 2022 | ||||||||||||||||||||||
|
(In millions) |
Estimated Fair Value | Gross Unrealized Losses | Estimated Fair Value | Gross Unrealized Losses | |||||||||||||||||||
| U.S. Government, Government agencies and Government-sponsored enterprises | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| AAA |
|
|
|
|
|||||||||||||||||||
| AA |
|
|
|
|
|||||||||||||||||||
| A |
|
|
|
|
|||||||||||||||||||
| BBB |
|
|
|
|
|||||||||||||||||||
| Non-investment grade |
|
|
|
|
|||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| (In millions) | Corporate and other bonds | Asset-backed | Total | ||||||||||||||
| Allowance for credit losses: | |||||||||||||||||
| Balance as of July 1, 2023 | $ |
|
$ |
|
$ |
|
|||||||||||
| Additions to the allowance for credit losses: | |||||||||||||||||
| Securities for which credit losses were not previously recorded |
|
|
|
||||||||||||||
| Available-for-sale securities accounted for as PCD assets |
|
|
|
||||||||||||||
| Reductions to the allowance for credit losses: | |||||||||||||||||
| Securities sold during the period (realized) |
|
|
|
||||||||||||||
| Intent to sell or more likely than not will be required to sell the security before recovery of its amortized cost basis |
|
|
|
||||||||||||||
| Write-offs charged against the allowance |
|
|
|
||||||||||||||
| Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period |
|
|
|
||||||||||||||
|
Balance as of September 30, 2023
|
$ |
|
$ |
|
$ |
|
|||||||||||
| (In millions) | Corporate and other bonds | Asset-backed | Total | ||||||||||||||
| Allowance for credit losses: | |||||||||||||||||
| Balance as of July 1, 2022 | $ |
|
$ |
|
$ |
|
|||||||||||
| Additions to the allowance for credit losses: | |||||||||||||||||
| Securities for which credit losses were not previously recorded |
|
|
|
||||||||||||||
| Available-for-sale securities accounted for as PCD assets |
|
|
|
||||||||||||||
| Reductions to the allowance for credit losses: | |||||||||||||||||
| Securities sold during the period (realized) |
|
|
|
||||||||||||||
| Intent to sell or more likely than not will be required to sell the security before recovery of its amortized cost basis |
|
|
|
||||||||||||||
| Write-offs charged against the allowance |
|
|
|
||||||||||||||
| Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period |
|
(
|
(
|
||||||||||||||
|
Balance as of September 30, 2022
|
$ |
|
$ |
|
$ |
|
|||||||||||
| (In millions) | Corporate and other bonds | Asset-backed | Total | ||||||||||||||
| Allowance for credit losses: | |||||||||||||||||
| Balance as of January 1, 2023 | $ |
|
$ |
|
$ |
|
|||||||||||
| Additions to the allowance for credit losses: | |||||||||||||||||
| Securities for which credit losses were not previously recorded |
|
|
|
||||||||||||||
| Available-for-sale securities accounted for as PCD assets |
|
|
|
||||||||||||||
| Reductions to the allowance for credit losses: | |||||||||||||||||
| Securities sold during the period (realized) |
|
|
|
||||||||||||||
| Intent to sell or more likely than not will be required to sell the security before recovery of its amortized cost basis |
|
|
|
||||||||||||||
| Write-offs charged against the allowance |
|
|
|
||||||||||||||
| Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period |
|
|
|
||||||||||||||
|
Balance as of September 30, 2023
|
$ |
|
$ |
|
$ |
|
|||||||||||
| (In millions) | Corporate and other bonds | Asset-backed | Total | ||||||||||||||
| Allowance for credit losses: | |||||||||||||||||
| Balance as of January 1, 2022 | $ |
|
$ |
|
$ |
|
|||||||||||
| Additions to the allowance for credit losses: | |||||||||||||||||
| Securities for which credit losses were not previously recorded |
|
|
|
||||||||||||||
| Available-for-sale securities accounted for as PCD assets |
|
|
|
||||||||||||||
| Reductions to the allowance for credit losses: | |||||||||||||||||
| Securities sold during the period (realized) |
|
|
|
||||||||||||||
| Intent to sell or more likely than not will be required to sell the security before recovery of its amortized cost basis |
|
|
|
||||||||||||||
| Write-offs charged against the allowance |
|
|
|
||||||||||||||
| Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period |
|
(
|
(
|
||||||||||||||
|
Balance as of September 30, 2022
|
$ |
|
$ |
|
$ |
|
|||||||||||
| September 30, 2023 | December 31, 2022 | ||||||||||||||||||||||
| (In millions) |
Cost or
Amortized Cost |
Estimated
Fair Value |
Cost or
Amortized Cost |
Estimated
Fair Value |
|||||||||||||||||||
| Due in one year or less | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Due after one year through five years |
|
|
|
|
|||||||||||||||||||
| Due after five years through ten years |
|
|
|
|
|||||||||||||||||||
| Due after ten years |
|
|
|
|
|||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| September 30, 2023 |
Mortgage Loans Amortized Cost Basis by Origination Year
(1)
|
||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2021 | 2020 | 2019 | Prior | Total | ||||||||||||||||||||||||||||||||||
| DSCR ≥1.6x | |||||||||||||||||||||||||||||||||||||||||
| LTV less than 55% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| LTV 55% to 65% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| LTV greater than 65% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| DSCR 1.2x - 1.6x | |||||||||||||||||||||||||||||||||||||||||
| LTV less than 55% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| LTV 55% to 65% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| LTV greater than 65% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| DSCR ≤1.2 | |||||||||||||||||||||||||||||||||||||||||
| LTV less than 55% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| LTV 55% to 65% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| LTV greater than 65% |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| September 30, 2023 |
Total
Assets/Liabilities at Fair Value |
||||||||||||||||||||||
| (In millions) | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||||
| Corporate bonds and other | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| States, municipalities and political subdivisions |
|
|
|
|
|||||||||||||||||||
| Asset-backed |
|
|
|
|
|||||||||||||||||||
| Total fixed maturity securities |
|
|
|
|
|||||||||||||||||||
| Equity securities: | |||||||||||||||||||||||
| Common stock |
|
|
|
|
|||||||||||||||||||
| Non-redeemable preferred stock |
|
|
|
|
|||||||||||||||||||
| Total equity securities |
|
|
|
|
|||||||||||||||||||
| Short term and other |
|
|
|
|
|||||||||||||||||||
| Total assets | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Liabilities | |||||||||||||||||||||||
| Other liabilities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Total liabilities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| December 31, 2022 |
Total
Assets/Liabilities at Fair Value |
||||||||||||||||||||||
| (In millions) | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||||
| Corporate bonds and other | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| States, municipalities and political subdivisions |
|
|
|
|
|||||||||||||||||||
| Asset-backed |
|
|
|
|
|||||||||||||||||||
| Total fixed maturity securities |
|
|
|
|
|||||||||||||||||||
| Equity securities: | |||||||||||||||||||||||
| Common stock |
|
|
|
|
|||||||||||||||||||
| Non-redeemable preferred stock |
|
|
|
|
|||||||||||||||||||
| Total equity securities |
|
|
|
|
|||||||||||||||||||
| Short term and other |
|
|
|
|
|||||||||||||||||||
| Total assets | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Liabilities | |||||||||||||||||||||||
| Other liabilities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Total liabilities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
|
Level 3
(In millions)
|
Corporate bonds and other | States, municipalities and political subdivisions | Asset-backed | Equity securities | Total | ||||||||||||||||||||||||||||||
| Balance as of July 1, 2023 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses): | |||||||||||||||||||||||||||||||||||
| Reported in Net investment gains (losses) |
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Reported in Net investment income |
|
|
|
(
|
|
||||||||||||||||||||||||||||||
| Reported in Other comprehensive income (loss) |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses) |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Purchases |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Sales |
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||
| Settlements |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Transfers into Level 3 |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Transfers out of Level 3 |
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Balance as of September 30, 2023 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2023 recognized in Net income (loss) in the period | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2023 recognized in Other comprehensive income (loss) in the period |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
|
Level 3
(In millions)
|
Corporate bonds and other | States, municipalities and political subdivisions | Asset-backed | Equity securities | Total | ||||||||||||||||||||||||||||||
| Balance as of July 1, 2022 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses): | |||||||||||||||||||||||||||||||||||
| Reported in Net investment gains (losses) |
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||
| Reported in Net investment income |
|
|
|
(
|
|
||||||||||||||||||||||||||||||
| Reported in Other comprehensive income (loss) |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses) |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Purchases |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Sales |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Settlements |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Transfers into Level 3 |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Transfers out of Level 3 |
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Balance as of September 30, 2022 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2022 recognized in Net income (loss) in the period | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2022 recognized in Other comprehensive income (loss) in the period |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
|
Level 3
(In millions)
|
Corporate bonds and other | States, municipalities and political subdivisions | Asset-backed | Equity securities | Total | ||||||||||||||||||||||||||||||
| Balance as of January 1, 2023 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses): | |||||||||||||||||||||||||||||||||||
| Reported in Net investment gains (losses) |
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Reported in Net investment income |
|
|
|
(
|
|
||||||||||||||||||||||||||||||
| Reported in Other comprehensive income (loss) |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses) |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Purchases |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Sales |
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||
| Settlements |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Transfers into Level 3 |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Transfers out of Level 3 |
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Balance as of September 30, 2023 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2023 recognized in Net income (loss) in the period | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2023 recognized in Other comprehensive income (loss) in the period |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
|
Level 3
(In millions)
|
Corporate bonds and other | States, municipalities and political subdivisions | Asset-backed | Equity securities | Total | ||||||||||||||||||||||||||||||
| Balance as of January 1, 2022 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses): | |||||||||||||||||||||||||||||||||||
| Reported in Net investment gains (losses) |
(
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||
| Reported in Net investment income |
|
|
|
(
|
|
||||||||||||||||||||||||||||||
| Reported in Other comprehensive income (loss) |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Total realized and unrealized investment gains (losses) |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Purchases |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Sales |
(
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Settlements |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| Transfers into Level 3 |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Transfers out of Level 3 |
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||
| Balance as of September 30, 2022 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2022 recognized in Net income (loss) in the period | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||
| Unrealized gains (losses) on Level 3 assets and liabilities held as of September 30, 2022 recognized in Other comprehensive income (loss) in the period |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||
| September 30, 2023 |
Estimated Fair Value
(In millions) |
Valuation Technique(s) | Unobservable Input(s) |
Range
(Weighted Average) |
|||||||||||||||||||
| Fixed maturity securities | $ |
|
Discounted cash flow | Credit spread |
|
||||||||||||||||||
| December 31, 2022 |
Estimated Fair Value
(In millions) |
Valuation Technique(s) | Unobservable Input(s) |
Range
(Weighted Average) |
|||||||||||||||||||
| Fixed maturity securities | $ |
|
Discounted cash flow | Credit spread |
|
||||||||||||||||||
| September 30, 2023 |
Carrying
Amount |
Estimated Fair Value | |||||||||||||||||||||||||||
| (In millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||
| Mortgage loans | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Liabilities | |||||||||||||||||||||||||||||
| Short term debt | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Long term debt |
|
|
|
|
|
||||||||||||||||||||||||
| December 31, 2022 |
Carrying
Amount |
Estimated Fair Value | |||||||||||||||||||||||||||
| (In millions) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||
| Mortgage loans | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Liabilities | |||||||||||||||||||||||||||||
| Short term debt | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Long term debt |
|
|
|
|
|
||||||||||||||||||||||||
|
For the nine months ended September 30
|
|||||||||||
| (In millions) | 2023 |
2022
(1)
|
|||||||||
| Reserves, beginning of year: | |||||||||||
| Gross | $ |
|
$ |
|
|||||||
| Ceded |
|
|
|||||||||
| Net reserves, beginning of year |
|
|
|||||||||
| Net incurred claim and claim adjustment expenses: | |||||||||||
| Provision for insured events of current year |
|
|
|||||||||
| Increase (decrease) in provision for insured events of prior years |
|
(
|
|||||||||
| Amortization of discount |
|
|
|||||||||
|
Total net incurred
(2)
|
|
|
|||||||||
| Net payments attributable to: | |||||||||||
| Current year events |
(
|
(
|
|||||||||
| Prior year events |
(
|
(
|
|||||||||
| Total net payments |
(
|
(
|
|||||||||
| Foreign currency translation adjustment and other |
(
|
(
|
|||||||||
| Net reserves, end of period |
|
|
|||||||||
| Ceded reserves, end of period |
|
|
|||||||||
| Gross reserves, end of period | $ |
|
$ |
|
|||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Pretax (favorable) unfavorable development: | |||||||||||||||||||||||
| Specialty | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Commercial |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| International |
|
|
|
(
|
|||||||||||||||||||
| Corporate & Other |
|
|
|
|
|||||||||||||||||||
| Total pretax (favorable) unfavorable development | $ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Pretax (favorable) unfavorable development: | |||||||||||||||||||||||
| Medical Professional Liability | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Other Professional Liability and Management Liability |
|
|
|
|
|||||||||||||||||||
| Surety |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Warranty |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Other |
|
|
|
(
|
|||||||||||||||||||
| Total pretax (favorable) unfavorable development | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Pretax (favorable) unfavorable development: | |||||||||||||||||||||||
| Commercial Auto | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| General Liability |
|
|
|
|
|||||||||||||||||||
| Workers' Compensation |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Property and Other |
|
|
|
(
|
|||||||||||||||||||
| Total pretax (favorable) unfavorable development | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Pretax (favorable) unfavorable development: | |||||||||||||||||||||||
| Commercial | $ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Specialty |
|
|
|
(
|
|||||||||||||||||||
| Other |
|
|
(
|
|
|||||||||||||||||||
| Total pretax (favorable) unfavorable development | $ |
|
$ |
|
$ |
|
$ |
(
|
|||||||||||||||
|
(In millions)
|
2023 | 2022 | ||||||||||||
| Present value of future net premiums | ||||||||||||||
| Balance, January 1 | $ |
|
$ |
|
||||||||||
| Effect of changes in discount rate |
(
|
(
|
||||||||||||
| Balance, January 1, at original locked in discount rate |
|
|
||||||||||||
|
Effect of changes in cash flow assumptions
(1)
|
|
|
||||||||||||
|
Effect of actual variances from expected experience
(1)
|
(
|
(
|
||||||||||||
| Adjusted balance, January 1 |
|
|
||||||||||||
| Interest accrual |
|
|
||||||||||||
| Net premiums: earned during period |
(
|
(
|
||||||||||||
| Balance, end of period at original locked in discount rate |
|
|
||||||||||||
| Effect of changes in discount rate |
(
|
|
||||||||||||
| Balance, September 30 | $ |
|
$ |
|
||||||||||
| Present value of future benefits & expenses | ||||||||||||||
| Balance, January 1 | $ |
|
$ |
|
||||||||||
| Effect of changes in discount rate |
(
|
(
|
||||||||||||
| Balance, January 1, at original locked in discount rate |
|
|
||||||||||||
|
Effect of changes in cash flow assumptions
(1)
|
|
|
||||||||||||
|
Effect of actual variances from expected experience
(1)
|
(
|
(
|
||||||||||||
| Adjusted balance, January 1 |
|
|
||||||||||||
| Interest accrual |
|
|
||||||||||||
| Benefit & expense payments |
(
|
(
|
||||||||||||
| Balance, end of period at original locked in discount rate |
|
|
||||||||||||
| Effect of changes in discount rate |
(
|
(
|
||||||||||||
| Balance, September 30 | $ |
|
$ |
|
||||||||||
| Net LFPB, September 30 | $ |
|
$ |
|
||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
|
(In millions)
|
2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Earned premiums | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Interest expense |
|
|
|
|
|||||||||||||||||||
| As of September 30 | |||||||||||
|
(In millions)
|
2023 | 2022 | |||||||||
| Expected future benefit and expense payments | $ |
|
$ |
|
|||||||
| Expected future gross premiums |
|
|
|||||||||
| As of September 30 | As of December 31 | ||||||||||||||||
| 2023 | 2022 | 2022 | |||||||||||||||
| Original locked in discount rate |
|
% |
|
% |
|
% | |||||||||||
| Upper-medium grade fixed income instrument discount rate |
|
|
|
||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Net periodic pension cost (benefit) | |||||||||||||||||||||||
| Interest cost on projected benefit obligation | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Expected return on plan assets |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Amortization of net actuarial loss |
|
|
|
|
|||||||||||||||||||
| Total net periodic pension cost (benefit) | $ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Non-Service Cost (Benefit): | |||||||||||||||||||||||
| Insurance claims and policyholder's benefits | $ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| Other operating expenses |
|
(
|
|
(
|
|||||||||||||||||||
| Total net periodic pension cost (benefit) | $ |
|
$ |
(
|
$ |
|
$ |
(
|
|||||||||||||||
| (In millions) | Net unrealized gains (losses) on investments with an allowance for credit losses |
Net unrealized gains (losses) on other investments
(1)
|
Pension and postretirement benefits |
Cumulative impact of changes in discount rates used to measure long duration contracts
(1)
|
Cumulative foreign currency translation adjustment | Total | |||||||||||||||||||||||||||||
| Balance as of July 1, 2023 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
|
Amounts reclassified from accumulated other comprehensive income (loss) net of tax (expense) benefit of $
|
(
|
(
|
(
|
|
|
(
|
|||||||||||||||||||||||||||||
|
Other comprehensive income (loss) net of tax (expense) benefit of $
|
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
| Balance as of September 30, 2023 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| (In millions) | Net unrealized gains (losses) on investments with an allowance for credit losses |
Net unrealized gains (losses) on other investments
(1)
|
Pension and postretirement benefits |
Cumulative impact of changes in discount rates used to measure long duration contracts
(1)
|
Cumulative foreign currency translation adjustment | Total | |||||||||||||||||||||||||||||
| Balance as of July 1, 2022, as previously reported | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
|
Cumulative effect adjustment from accounting change for adoption of ASU 2018-12
(1)
net of tax (expense) benefit of $
|
|
|
|
(
|
|
(
|
|||||||||||||||||||||||||||||
| Balance as of July 1, 2022, as adjusted |
(
|
(
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
|
Amounts reclassified from accumulated other comprehensive income (loss) net of tax (expense) benefit of $
|
|
(
|
(
|
|
|
(
|
|||||||||||||||||||||||||||||
|
Other comprehensive income (loss) net of tax (expense) benefit of $
|
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
| Balance as of September 30, 2022 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| (In millions) | Net unrealized gains (losses) on investments with an allowance for credit losses |
Net unrealized gains (losses) on other investments
(1)
|
Pension and postretirement benefits |
Cumulative impact of changes in discount rates used to measure long duration contracts
(1)
|
Cumulative foreign currency translation adjustment | Total | |||||||||||||||||||||||||||||
| Balance as of January 1, 2023, as previously reported | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
|
Cumulative effect adjustment from accounting change for adoption of ASU 2018-12
(1)
net of tax (expense) benefit of $
|
|
|
|
(
|
|
(
|
|||||||||||||||||||||||||||||
| Balance as of January 1, 2023, as adjusted |
(
|
(
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
|
Amounts reclassified from accumulated other comprehensive income (loss) net of tax (expense) benefit of $
|
(
|
(
|
(
|
|
|
(
|
|||||||||||||||||||||||||||||
|
Other comprehensive income (loss) net of tax (expense) benefit of $
|
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
| Balance as of September 30, 2023 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| (In millions) | Net unrealized gains (losses) on investments with an allowance for credit losses |
Net unrealized gains (losses) on other investments
(1)
|
Pension and postretirement benefits |
Cumulative impact of changes in discount rates used to measure long duration contracts
(1)
|
Cumulative foreign currency translation adjustment | Total | |||||||||||||||||||||||||||||
| Balance as of January 1, 2022, as previously reported | $ |
(
|
$ |
|
$ |
(
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||
|
Cumulative effect adjustment from accounting change for adoption of ASU 2018-12
(1)
net of tax (expense) benefit of $
|
|
|
|
(
|
|
(
|
|||||||||||||||||||||||||||||
| Balance as of January 1, 2022, as adjusted |
(
|
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
|
Amounts reclassified from accumulated other comprehensive income (loss) net of tax (expense) benefit of $(
|
|
(
|
(
|
|
|
(
|
|||||||||||||||||||||||||||||
|
Other comprehensive income (loss) net of tax (expense) benefit of $
|
(
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
| Balance as of September 30, 2022 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Component of AOCI | Condensed Consolidated Statements of Operations Line Item Affected by Reclassifications | |||||||
| Net unrealized gains (losses) on investments with an allowance for credit losses and Net unrealized gains (losses) on other investments | Net investment gains (losses) | |||||||
| Pension and postretirement benefits | Other operating expenses and Insurance claims and policyholders' benefits | |||||||
| Three months ended September 30, 2023 |
Specialty |
Commercial |
International |
Life &
Group |
Corporate
& Other |
||||||||||||||||||||||||||||||||||||
| (In millions) | Eliminations | Total | |||||||||||||||||||||||||||||||||||||||
| Operating revenues | |||||||||||||||||||||||||||||||||||||||||
| Net earned premiums | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
| Net investment income |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty revenue |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other revenues |
|
|
(
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total operating revenues |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Claims, benefits and expenses | |||||||||||||||||||||||||||||||||||||||||
| Net incurred claims and benefits |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Policyholders’ dividends |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Amortization of deferred acquisition costs |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other insurance related expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Other expenses |
|
|
|
(
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total claims, benefits and expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Core income (loss) before income tax |
|
|
|
(
|
(
|
|
|
||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on core income (loss) |
(
|
(
|
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||
| Core income (loss) | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|
||||||||||||||||||||||||||||
| Net investment gains (losses) |
(
|
||||||||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on net investment gains (losses) |
|
||||||||||||||||||||||||||||||||||||||||
| Net investment gains (losses), after tax |
(
|
||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ |
|
|||||||||||||||||||||||||||||||||||||||
| Three months ended September 30, 2022 |
Specialty |
Commercial |
International |
Life &
Group
(1)
|
Corporate
& Other |
||||||||||||||||||||||||||||||||||||
| (In millions) | Eliminations |
Total
(1)
|
|||||||||||||||||||||||||||||||||||||||
| Operating revenues | |||||||||||||||||||||||||||||||||||||||||
| Net earned premiums | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Net investment income |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty revenue |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other revenues |
(
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total operating revenues |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Claims, benefits and expenses | |||||||||||||||||||||||||||||||||||||||||
| Net incurred claims and benefits |
|
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||||
| Policyholders’ dividends |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Amortization of deferred acquisition costs |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other insurance related expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Other expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total claims, benefits and expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Core income (loss) before income tax |
|
|
|
(
|
(
|
|
|
||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on core income (loss) |
(
|
(
|
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||
| Core income (loss) | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|
||||||||||||||||||||||||||||
| Net investment gains (losses) |
(
|
||||||||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on net investment gains (losses) |
|
||||||||||||||||||||||||||||||||||||||||
| Net investment gains (losses), after tax |
(
|
||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ |
(
|
|||||||||||||||||||||||||||||||||||||||
| Nine months ended September 30, 2023 |
Specialty |
Commercial |
International |
Life &
Group |
Corporate
& Other |
||||||||||||||||||||||||||||||||||||
| (In millions) | Eliminations | Total | |||||||||||||||||||||||||||||||||||||||
| Operating revenues | |||||||||||||||||||||||||||||||||||||||||
| Net earned premiums | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
| Net investment income |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty revenue |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other revenues |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total operating revenues |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Claims, benefits and expenses | |||||||||||||||||||||||||||||||||||||||||
| Net incurred claims and benefits |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Policyholders’ dividends |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Amortization of deferred acquisition costs |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other insurance related expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Other expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total claims, benefits and expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Core income (loss) before income tax |
|
|
|
(
|
(
|
|
|
||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on core income (loss) |
(
|
(
|
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||
| Core income (loss) | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|
||||||||||||||||||||||||||||
| Net investment gains (losses) |
(
|
||||||||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on net investment gains (losses) |
|
||||||||||||||||||||||||||||||||||||||||
| Net investment gains (losses), after tax |
(
|
||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ |
|
|||||||||||||||||||||||||||||||||||||||
| September 30, 2023 | |||||||||||||||||||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||||||||||||||||||
| Reinsurance receivables | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Insurance receivables |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Deferred acquisition costs |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Goodwill |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Deferred non-insurance warranty acquisition expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Insurance reserves | |||||||||||||||||||||||||||||||||||||||||
| Claim and claim adjustment expenses |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Unearned premiums |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Future policy benefits |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Deferred non-insurance warranty revenue |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Nine months ended September 30, 2022 |
Specialty |
Commercial |
International |
Life &
Group
(1)
|
Corporate
& Other |
||||||||||||||||||||||||||||||||||||
| (In millions) | Eliminations |
Total
(1)
|
|||||||||||||||||||||||||||||||||||||||
| Operating revenues | |||||||||||||||||||||||||||||||||||||||||
| Net earned premiums | $ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Net investment income |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty revenue |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other revenues |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total operating revenues |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Claims, benefits and expenses | |||||||||||||||||||||||||||||||||||||||||
| Net incurred claims and benefits |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Policyholders’ dividends |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Amortization of deferred acquisition costs |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Non-insurance warranty expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Other insurance related expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Other expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total claims, benefits and expenses |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Core income (loss) before income tax |
|
|
|
(
|
(
|
|
|
||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on core income (loss) |
(
|
(
|
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||
| Core income (loss) | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|
||||||||||||||||||||||||||||
| Net investment gains (losses) |
(
|
||||||||||||||||||||||||||||||||||||||||
| Income tax (expense) benefit on net investment gains (losses) |
|
||||||||||||||||||||||||||||||||||||||||
| Net investment gains (losses), after tax |
(
|
||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ |
|
|||||||||||||||||||||||||||||||||||||||
| December 31, 2022 | |||||||||||||||||||||||||||||||||||||||||
| (In millions) | |||||||||||||||||||||||||||||||||||||||||
| Reinsurance receivables | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Insurance receivables |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Deferred acquisition costs |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Goodwill |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Deferred non-insurance warranty acquisition expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Insurance reserves | |||||||||||||||||||||||||||||||||||||||||
| Claim and claim adjustment expenses |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Unearned premiums |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Future policy benefits |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Deferred non-insurance warranty revenue |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Specialty | |||||||||||||||||||||||
| Management & Professional Liability | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Surety |
|
|
|
|
|||||||||||||||||||
| Warranty & Alternative Risks |
|
|
|
|
|||||||||||||||||||
| Specialty revenues |
|
|
|
|
|||||||||||||||||||
| Commercial | |||||||||||||||||||||||
| Middle Market |
|
|
|
|
|||||||||||||||||||
| Construction |
|
|
|
|
|||||||||||||||||||
| Small Business |
|
|
|
|
|||||||||||||||||||
| Other Commercial |
|
|
|
|
|||||||||||||||||||
| Commercial revenues |
|
|
|
|
|||||||||||||||||||
| International | |||||||||||||||||||||||
| Canada |
|
|
|
|
|||||||||||||||||||
| Europe |
|
|
|
|
|||||||||||||||||||
| Hardy |
|
|
|
|
|||||||||||||||||||
| International revenues |
|
|
|
|
|||||||||||||||||||
| Life & Group revenues |
|
|
|
|
|||||||||||||||||||
| Corporate & Other revenues |
|
|
|
|
|||||||||||||||||||
| Eliminations |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Total operating revenues |
|
|
|
|
|||||||||||||||||||
| Net investment gains (losses) |
(
|
(
|
(
|
(
|
|||||||||||||||||||
| Total revenues | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Nine months ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 |
2022
(1)
|
2023 |
2022
(1)
|
|||||||||||||||||||
| Operating Revenues | |||||||||||||||||||||||
| Net earned premiums | $ | 2,406 | $ | 2,221 | $ | 7,001 | $ | 6,435 | |||||||||||||||
| Net investment income | 553 | 422 | 1,653 | 1,302 | |||||||||||||||||||
| Non-insurance warranty revenue | 407 | 399 | 1,221 | 1,173 | |||||||||||||||||||
| Other revenues | 8 | 11 | 22 | 24 | |||||||||||||||||||
| Total operating revenues | 3,374 | 3,053 | 9,897 | 8,934 | |||||||||||||||||||
| Claims, Benefits and Expenses | |||||||||||||||||||||||
|
Net incurred claims and benefits (re-measurement gain (loss) of $(41), $(211), $(75), and $(205))
|
1,818 | 1,873 | 5,236 | 4,939 | |||||||||||||||||||
| Policyholders' dividends | 8 | 7 | 22 | 20 | |||||||||||||||||||
| Amortization of deferred acquisition costs | 426 | 383 | 1,208 | 1,101 | |||||||||||||||||||
| Non-insurance warranty expense | 386 | 371 | 1,154 | 1,092 | |||||||||||||||||||
| Other insurance related expenses | 294 | 297 | 917 | 863 | |||||||||||||||||||
| Other expenses | 78 | 77 | 197 | 222 | |||||||||||||||||||
| Total claims, benefits and expenses | 3,010 | 3,008 | 8,734 | 8,237 | |||||||||||||||||||
| Core income before income tax | 364 | 45 | 1,163 | 697 | |||||||||||||||||||
| Income tax expense on core income | (75) | (2) | (241) | (126) | |||||||||||||||||||
| Core income | 289 | 43 | 922 | 571 | |||||||||||||||||||
| Net investment losses | (38) | (96) | (105) | (166) | |||||||||||||||||||
| Income tax benefit on net investment losses | 7 | 11 | 21 | 38 | |||||||||||||||||||
| Net investment losses, after tax | (31) | (85) | (84) | (128) | |||||||||||||||||||
| Net income (loss) | $ | 258 | $ | (42) | $ | 838 | $ | 443 | |||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions, except ratios, rate, renewal premium change and retention) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Gross written premiums | $ | 1,775 | $ | 1,890 | $ | 5,324 | $ | 5,640 | |||||||||||||||
| Gross written premiums excluding third-party captives | 949 | 958 | 2,796 | 2,816 | |||||||||||||||||||
| Net written premiums | 825 | 840 | 2,438 | 2,443 | |||||||||||||||||||
| Net earned premiums | 829 | 810 | 2,438 | 2,376 | |||||||||||||||||||
| Underwriting gain | 83 | 92 | 237 | 273 | |||||||||||||||||||
| Net investment income | 136 | 102 | 407 | 305 | |||||||||||||||||||
| Core income | 178 | 161 | 526 | 485 | |||||||||||||||||||
| Other performance metrics: | |||||||||||||||||||||||
| Loss ratio excluding catastrophes and development | 58.6 | % | 58.4 | % | 58.5 | % | 58.6 | % | |||||||||||||||
| Effect of catastrophe impacts | — | 0.2 | — | 0.1 | |||||||||||||||||||
| Effect of development-related items | (0.6) | (1.9) | (0.3) | (1.4) | |||||||||||||||||||
| Loss ratio | 58.0 | 56.7 | 58.2 | 57.3 | |||||||||||||||||||
| Expense ratio | 31.8 | 31.7 | 31.9 | 31.0 | |||||||||||||||||||
| Dividend ratio | 0.3 | 0.3 | 0.2 | 0.2 | |||||||||||||||||||
| Combined ratio | 90.1 | % | 88.7 | % | 90.3 | % | 88.5 | % | |||||||||||||||
| Combined ratio excluding catastrophes and development | 90.7 | % | 90.4 | % | 90.6 | % | 89.8 | % | |||||||||||||||
| Rate | 1 | % | 5 | % | 1 | % | 7 | % | |||||||||||||||
| Renewal premium change | 2 | 6 | 2 | 8 | |||||||||||||||||||
| Retention | 87 | 88 | 88 | 86 | |||||||||||||||||||
| New business | $ | 121 | $ | 130 | $ | 349 | $ | 407 | |||||||||||||||
| (In millions) | September 30, 2023 | December 31, 2022 | |||||||||
| Gross case reserves | $ | 1,513 | $ | 1,529 | |||||||
| Gross IBNR reserves | 5,577 | 5,349 | |||||||||
| Total gross carried claim and claim adjustment expense reserves | $ | 7,090 | $ | 6,878 | |||||||
| Net case reserves | $ | 1,299 | $ | 1,310 | |||||||
| Net IBNR reserves | 4,471 | 4,253 | |||||||||
| Total net carried claim and claim adjustment expense reserves | $ | 5,770 | $ | 5,563 | |||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions, except ratios, rate, renewal premium change and retention) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Gross written premiums | $ | 1,343 | $ | 1,187 | $ | 4,504 | $ | 3,824 | |||||||||||||||
| Gross written premiums excluding third-party captives | 1,340 | 1,184 | 4,384 | 3,711 | |||||||||||||||||||
| Net written premiums | 1,071 | 962 | 3,588 | 3,097 | |||||||||||||||||||
| Net earned premiums | 1,170 | 1,023 | 3,336 | 2,901 | |||||||||||||||||||
| Underwriting gain (loss) | 13 | (23) | 96 | 94 | |||||||||||||||||||
| Net investment income | 156 | 112 | 470 | 343 | |||||||||||||||||||
| Core income | 133 | 80 | 443 | 350 | |||||||||||||||||||
| Other performance metrics: | |||||||||||||||||||||||
| Loss ratio excluding catastrophes and development | 61.5 | % | 61.5 | % | 61.5 | % | 61.5 | % | |||||||||||||||
| Effect of catastrophe impacts | 7.4 | 10.0 | 5.7 | 5.0 | |||||||||||||||||||
| Effect of development-related items | — | — | (0.2) | (0.5) | |||||||||||||||||||
| Loss ratio | 68.9 | 71.5 | 67.0 | 66.0 | |||||||||||||||||||
| Expense ratio | 29.5 | 29.9 | 29.6 | 30.1 | |||||||||||||||||||
| Dividend ratio | 0.5 | 0.5 | 0.5 | 0.5 | |||||||||||||||||||
| Combined ratio | 98.9 | % | 101.9 | % | 97.1 | % | 96.6 | % | |||||||||||||||
| Combined ratio excluding catastrophes and development | 91.5 | % | 91.9 | % | 91.6 | % | 92.1 | % | |||||||||||||||
| Rate | 8 | % | 4 | % | 8 | % | 5 | % | |||||||||||||||
| Renewal premium change | 9 | 7 | 10 | 8 | |||||||||||||||||||
| Retention | 83 | 86 | 85 | 86 | |||||||||||||||||||
| New business | $ | 292 | $ | 246 | $ | 945 | $ | 754 | |||||||||||||||
| (In millions) | September 30, 2023 | December 31, 2022 | |||||||||
| Gross case reserves | $ | 3,271 | $ | 3,156 | |||||||
| Gross IBNR reserves | 6,631 | 6,239 | |||||||||
| Total gross carried claim and claim adjustment expense reserves | $ | 9,902 | $ | 9,395 | |||||||
| Net case reserves | $ | 2,845 | $ | 2,809 | |||||||
| Net IBNR reserves | 5,965 | 5,621 | |||||||||
| Total net carried claim and claim adjustment expense reserves | $ | 8,810 | $ | 8,430 | |||||||
|
Periods ended September 30
|
Three Months | Nine Months | |||||||||||||||||||||
| (In millions, except ratios, rate, renewal premium change and retention) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Gross written premiums | $ | 306 | $ | 288 | $ | 1,125 | $ | 1,033 | |||||||||||||||
| Net written premiums | 282 | 258 | 912 | 839 | |||||||||||||||||||
| Net earned premiums | 296 | 270 | 888 | 803 | |||||||||||||||||||
| Underwriting gain | 35 | 15 | 66 | 58 | |||||||||||||||||||
| Net investment income | 26 | 16 | 74 | 44 | |||||||||||||||||||
| Core income | 40 | 19 | 102 | 63 | |||||||||||||||||||
| Other performance metrics: | |||||||||||||||||||||||
| Loss ratio excluding catastrophes and development | 57.9 | % | 58.6 | % | 57.8 | % | 58.6 | % | |||||||||||||||
| Effect of catastrophe impacts | 2.3 | 4.1 | 2.7 | 2.7 | |||||||||||||||||||
| Effect of development-related items | — | — | 1.7 | (0.6) | |||||||||||||||||||
| Loss ratio | 60.2 | 62.7 | 62.2 | 60.7 | |||||||||||||||||||
| Expense ratio | 28.1 | 31.7 | 30.3 | 32.1 | |||||||||||||||||||
| Combined ratio | 88.3 | % | 94.4 | % | 92.5 | % | 92.8 | % | |||||||||||||||
| Combined ratio excluding catastrophes and development | 86.0 | % | 90.3 | % | 88.1 | % | 90.7 | % | |||||||||||||||
| Rate | 2 | % | 6 | % | 4 | % | 7 | % | |||||||||||||||
| Renewal premium change | 7 | 15 | 7 | 11 | |||||||||||||||||||
| Retention | 84 | 83 | 83 | 79 | |||||||||||||||||||
| New business | $ | 62 | $ | 79 | $ | 239 | $ | 245 | |||||||||||||||
| (In millions) | September 30, 2023 | December 31, 2022 | |||||||||
| Gross case reserves | $ | 822 | $ | 817 | |||||||
| Gross IBNR reserves | 1,750 | 1,586 | |||||||||
| Total gross carried claim and claim adjustment expense reserves | $ | 2,572 | $ | 2,403 | |||||||
| Net case reserves | $ | 689 | $ | 686 | |||||||
| Net IBNR reserves | 1,469 | 1,317 | |||||||||
| Total net carried claim and claim adjustment expense reserves | $ | 2,158 | $ | 2,003 | |||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 |
2022
(1)
|
2023 |
2022
(1)
|
|||||||||||||||||||
| Net earned premiums | $ | 112 | $ | 118 | $ | 340 | $ | 356 | |||||||||||||||
| Claims, benefits and expenses | 371 | 556 | 1,087 | 1,236 | |||||||||||||||||||
| Net investment income | 216 | 187 | 659 | 600 | |||||||||||||||||||
| Core loss | (29) | (192) | (52) | (196) | |||||||||||||||||||
| September 30, 2023 | |||||
| Estimated reduction to pretax income | |||||
| Hypothetical revisions (In millions) | |||||
| Morbidity: | |||||
| 2.5% increase in morbidity | $ | 275 | |||
| 5% increase in morbidity | 600 | ||||
| Persistency: | |||||
| 5% decrease in active life mortality and lapse | $ | 150 | |||
| 10% decrease in active life mortality and lapse | 300 | ||||
| Premium Rate Actions: | |||||
| 25% decrease in anticipated future premium rate increases | $ | 25 | |||
| 50% decrease in anticipated future premium rate increases | 50 | ||||
| September 30, 2023 | |||||||||||||||||
| (In millions) | Claim and claim adjustment expenses | Future policy benefits | Total | ||||||||||||||
| Long term care | $ | — | $ | 12,654 | $ | 12,654 | |||||||||||
| Structured settlement annuities and other | 552 | — | 552 | ||||||||||||||
| Total | 552 | 12,654 | 13,206 | ||||||||||||||
| Ceded reserves | 97 | — | 97 | ||||||||||||||
| Total gross reserves | $ | 649 | $ | 12,654 | $ | 13,303 | |||||||||||
| December 31, 2022 | |||||||||||||||||
| (In millions) | Claim and claim adjustment expenses | Future policy benefits | Total | ||||||||||||||
|
Long term care
(1) (2)
|
$ | — | $ | 13,480 | $ | 13,480 | |||||||||||
| Structured settlement annuities and other | 594 | — | 594 | ||||||||||||||
| Total | 594 | 13,480 | 14,074 | ||||||||||||||
| Ceded reserves | 101 | — | 101 | ||||||||||||||
| Total gross reserves | $ | 695 | $ | 13,480 | $ | 14,175 | |||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Insurance claims and policyholders' benefits | $ | 10 | $ | (13) | $ | 32 | $ | 36 | |||||||||||||||||||||
| Net investment income | 19 | 5 | 43 | 10 | |||||||||||||||||||||||||
| Interest expense | 35 | 28 | 93 | 84 | |||||||||||||||||||||||||
| Core loss | (33) | (25) | (97) | (131) | |||||||||||||||||||||||||
| (In millions) | September 30, 2023 | December 31, 2022 | |||||||||
| Gross case reserves | $ | 1,366 | $ | 1,428 | |||||||
| Gross IBNR reserves | 1,257 | 1,321 | |||||||||
| Total gross carried claim and claim adjustment expense reserves | $ | 2,623 | $ | 2,749 | |||||||
| Net case reserves | $ | 123 | $ | 137 | |||||||
| Net IBNR reserves | 241 | 202 | |||||||||
| Total net carried claim and claim adjustment expense reserves | $ | 364 | $ | 339 | |||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Fixed income securities: | |||||||||||||||||||||||
| Taxable fixed income securities | $ | 457 | $ | 410 | $ | 1,331 | $ | 1,163 | |||||||||||||||
| Tax-exempt fixed income securities | 43 | 55 | 138 | 194 | |||||||||||||||||||
| Total fixed income securities | 500 | 465 | 1,469 | 1,357 | |||||||||||||||||||
| Limited partnership and common stock investments | 28 | (44) | 124 | (51) | |||||||||||||||||||
| Other, net of investment expense | 25 | 1 | 60 | (4) | |||||||||||||||||||
| Net investment income | $ | 553 | $ | 422 | $ | 1,653 | $ | 1,302 | |||||||||||||||
| Effective income yield for the fixed income securities portfolio | 4.7 | % | 4.4 | % | 4.6 | % | 4.3 | % | |||||||||||||||
| Limited partnership and common stock return | 1.3 | % | (2.1) | % | 5.8 | % | (2.4) | % | |||||||||||||||
| Periods ended September 30 | Three Months | Nine Months | |||||||||||||||||||||
| (In millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Fixed maturity securities: | |||||||||||||||||||||||
| Corporate bonds and other | $ | (11) | $ | (41) | $ | (46) | $ | (68) | |||||||||||||||
| States, municipalities and political subdivisions | (4) | 6 | 3 | 28 | |||||||||||||||||||
| Asset-backed | (22) | (17) | (43) | (29) | |||||||||||||||||||
| Total fixed maturity securities | (37) | (52) | (86) | (69) | |||||||||||||||||||
| Non-redeemable preferred stock | 2 | (2) | (9) | (111) | |||||||||||||||||||
| Derivatives, short term and other | 2 | (34) | 1 | 22 | |||||||||||||||||||
| Mortgage loans | (5) | (8) | (11) | (8) | |||||||||||||||||||
| Net investment losses | (38) | (96) | (105) | (166) | |||||||||||||||||||
| Income tax benefit on net investment losses |
|
|
|
|
|||||||||||||||||||
| Net investment losses, after tax | $ | (31) | $ | (85) | $ | (84) | $ | (128) | |||||||||||||||
| September 30, 2023 | December 31, 2022 | ||||||||||||||||||||||
|
(In millions) |
Estimated Fair Value | Net Unrealized Gains (Losses) | Estimated Fair Value | Net Unrealized Gains (Losses) | |||||||||||||||||||
| U.S. Government, Government agencies and Government-sponsored enterprises | $ | 2,672 | $ | (464) | $ | 2,419 | $ | (336) | |||||||||||||||
| AAA | 2,464 | (340) | 2,398 | (208) | |||||||||||||||||||
| AA | 5,916 | (950) | 6,342 | (663) | |||||||||||||||||||
| A | 9,372 | (772) | 9,043 | (531) | |||||||||||||||||||
| BBB | 15,632 | (1,776) | 15,651 | (1,447) | |||||||||||||||||||
| Non-investment grade | 1,800 | (190) | 1,774 | (219) | |||||||||||||||||||
| Total | $ | 37,856 | $ | (4,492) | $ | 37,627 | $ | (3,404) | |||||||||||||||
| September 30, 2023 | |||||||||||
| (In millions) | Estimated Fair Value | Gross Unrealized Losses | |||||||||
| U.S. Government, Government agencies and Government-sponsored enterprises | $ | 2,620 | $ | 466 | |||||||
| AAA | 1,893 | 382 | |||||||||
| AA | 4,458 | 1,037 | |||||||||
| A | 7,240 | 913 | |||||||||
| BBB | 13,704 | 1,881 | |||||||||
| Non-investment grade | 1,202 | 209 | |||||||||
| Total | $ | 31,117 | $ | 4,888 | |||||||
| September 30, 2023 | |||||||||||
| (In millions) | Estimated Fair Value | Gross Unrealized Losses | |||||||||
| Due in one year or less | $ | 953 | $ | 45 | |||||||
| Due after one year through five years | 9,059 | 701 | |||||||||
| Due after five years through ten years | 9,535 | 1,550 | |||||||||
| Due after ten years | 11,570 | 2,592 | |||||||||
| Total | $ | 31,117 | $ | 4,888 | |||||||
| September 30, 2023 | |||||||||||
| (In millions) | Estimated Fair Value | Net Unrealized Gains (Losses) | |||||||||
| Commercial mortgage-backed: | |||||||||||
| Single asset, single borrower: | |||||||||||
| Office | $ | 293 | $ | (83) | |||||||
| Retail | 269 | (37) | |||||||||
| Lodging | 216 | (23) | |||||||||
| Industrial | 91 | (6) | |||||||||
| Multifamily | 58 | (4) | |||||||||
| Total single asset, single borrower | 927 | (153) | |||||||||
| Conduits (multi property, multi borrower pools) | 627 | (119) | |||||||||
| Total commercial mortgage-backed | $ | 1,554 | $ | (272) | |||||||
| September 30, 2023 | |||||||||||
| (In millions) | Estimated Fair Value | Net Unrealized Gains (Losses) | |||||||||
| Commercial mortgage-backed: | |||||||||||
| AAA | $ | 504 | $ | (39) | |||||||
| AA | 578 | (120) | |||||||||
| A | 198 | (37) | |||||||||
| BBB | 222 | (52) | |||||||||
| Non-investment grade | 52 | (24) | |||||||||
| Total commercial mortgage-backed | $ | 1,554 | $ | (272) | |||||||
| September 30, 2023 | |||||||||||
| (In millions) | Estimated Fair Value | Net Unrealized Gains (Losses) | |||||||||
| Corporate and other bonds - REITs: | |||||||||||
| Retail | $ | 462 | $ | (53) | |||||||
| Office | 237 | (32) | |||||||||
| Industrial | 83 | (8) | |||||||||
|
Other
(1)
|
412 | (41) | |||||||||
| Total corporate and other bonds - REITs | $ | 1,194 | $ | (134) | |||||||
| September 30, 2023 | |||||||||||
| (In millions) | Estimated Fair Value | Net Unrealized Gains (Losses) | |||||||||
| Corporate and other bonds - REITs: | |||||||||||
| AA | $ | 10 | $ | (1) | |||||||
| A | 244 | (18) | |||||||||
| BBB | 918 | (112) | |||||||||
| Non-investment grade | 22 | (3) | |||||||||
| Total corporate and other bonds - REITs | $ | 1,194 | $ | (134) | |||||||
| September 30, 2023 | |||||||||||
| (In millions) | Amortized Cost | Percentage of Total | |||||||||
| Mortgage loans: | |||||||||||
| Retail | $ | 470 | 45 | % | |||||||
| Office | 246 | 24 | % | ||||||||
| Industrial | 133 | 13 | % | ||||||||
| Other | 181 | 18 | % | ||||||||
| Total mortgage loans | 1,030 | 100 | % | ||||||||
| Less: Allowance for expected credit losses | (35) | ||||||||||
| Total mortgage loans - net of allowance | $ | 995 | |||||||||
| September 30, 2023 | December 31, 2022 | ||||||||||||||||||||||
| (In millions) | Estimated Fair Value |
Effective
Duration (In years) |
Estimated Fair Value |
Effective
Duration (In years) |
|||||||||||||||||||
| Investments supporting Life & Group | $ | 13,737 | 9.8 | $ | 14,511 | 9.9 | |||||||||||||||||
| Other investments | 26,459 | 4.6 | 25,445 | 4.7 | |||||||||||||||||||
| Total | $ | 40,196 | 6.3 | $ | 39,956 | 6.6 | |||||||||||||||||
| CNA Financial Corporation | ||||||||
| Dated: October 30, 2023 | By | /s/ Scott R. Lindquist | ||||||
|
Scott R. Lindquist
Executive Vice President and Chief Financial Officer (Duly authorized officer and principal financial officer) |
||||||||
| Description of Exhibit | Exhibit Number | ||||
| 31.1 | |||||
| 31.2 | |||||
| 32.1 | |||||
| 32.2 | |||||
| XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | 101.INS | ||||
| Inline XBRL Taxonomy Extension Schema | 101.SCH | ||||
| Inline XBRL Taxonomy Extension Calculation Linkbase | 101.CAL | ||||
| Inline XBRL Taxonomy Extension Definition Linkbase | 101.DEF | ||||
| Inline XBRL Taxonomy Label Linkbase | 101.LAB | ||||
| Inline XBRL Taxonomy Extension Presentation Linkbase | 101.PRE | ||||
| Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | 104.1 | ||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|